Jonathan is Chairman and CEO of Erasca, which he co-founded in July 2018 with a mission to erase cancer. He is a physician-turned-venturepreneur who, since 2003, has been a leader and founding investor of four other biotechnology startups that delivered novel therapies for the benefit of patients globally, raised a combined $1 billion in capital and generated more than $4 billion of shareholder value. Jonathan’s most recent operational role was serving as Chairman, President, CEO and Co-founder of Ignyta from August 2011 until its acquisition by Roche in February 2018 for $1.7 billion, then overseeing Ignyta’s integration into Roche and Genentech. Previously, he was Chairman and Co-founder of Bonti from August 2015 until its October 2018 acquisition by Allergan; Chairman, CEO and Co-founder of Eclipse Therapeutics from March 2011 to its September 2012 acquisition by Bionomics; and President, CEO and Chairman-then-Director of Halozyme Therapeutics from May 2003 to December 2010.
Jonathan is dedicated to building world-class, mission-driven ventures as Managing Partner for City Hill Ventures, an impact-minded investment firm he founded in December 2010, and as Venture Partner at ARCH Venture Partners, which he joined in December 2018. In these capacities, he serves as Chairman and Co-founder of Pretzel Therapeutics, in addition to his responsibilities at Erasca. Jonathan also is Co-President of City Hill Foundation and an advisor to nonprofit organizations, including Stanford University, University of California, San Diego, The Scripps Research Institute and UrbanLife. Earlier in his career, Jonathan was a management consultant at McKinsey & Company, an NIH Postdoctoral Fellow at Harvard Medical School and Dana Farber Cancer Institute, and a general surgery resident at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. He holds B.S. and M.S. degrees from Stanford University, an M.D. from McGill University and an M.P.H. from Harvard University.